attention deficit hyperactivity disorder
Neurology · 2006–2020
4decisions
2medicines
1carried consumer input
18individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6–18 years who have demonstrated a response to immediate-release methylphenidate… | Mar 2020 | Recommended | 18 individuals |
| guanfacine Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years who are contraindicated to stimulants, intolerant to… | Jul 2017 | Recommended with restriction | none received |
| methylphenidate hydrochloride treatment of attention deficit hyperactivity disorder in children and adolescents aged 6-18 years who require continuous coverage over 12 hours | Mar 2006 | Not recommended | no section in document |
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years who require continuous coverage over 12 hours. | Mar 2006 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.